Market Overview

UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp.

Related GEVA
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk
JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue

In a report published Wednesday, Wedbush Securities reiterated its Outperform rating on Synageva BioPharma Corp. (NASDAQ: GEVA), and raised its price target from $42.00 to $50.00.

Wedbush Securities noted, “In an abstract at AALSD, the company reported that in 3 of 7 subjects where MRI data were available, there was a reduction in liver fat fractions, indicating that, in addition to normalization of liver enzymes and lipids, patients could be seeing additional clinical benefit with SBC-102 treatment. We expect updates to these data as they become available at AALSD and LDN (Q1:13).”

Synageva BioPharma Corp. closed on Tuesday at $42.85.

Latest Ratings for GEVA

May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (GEVA)

Get Benzinga's Newsletters